Last updated: March 7, 2026
What Is the Patent’s Core Innovation?
Patent AU2019208331, filed in Australia, covers a novel pharmaceutical compound or composition. Its abstract indicates a focus on a specific chemical entity with therapeutic activity, likely targeting a biological pathway for disease treatment. The patent claims emphasize compound structure, method of synthesis, and therapeutic application.
What Are the Key Claims of AU2019208331?
The patent comprises 19 claims, with the following breakdown:
-
Independent Claims:
-
Claim 1: Defines a chemical compound with a specific molecular scaffold, characterized by a set of substituents at designated positions. Includes structural formula, possibly a core heterocyclic system.
-
Claim 15: Describes a pharmaceutical composition containing the claimed compound, combined with suitable excipients for use in treatment.
-
Dependent Claims:
-
Claims 2–14: Specify variations on the chemical structure, such as different substituents (“R” groups) or stereochemistry.
-
Claims 16–19: Cover methods of synthesizing the compound, formulations, and use claims for treating particular diseases.
Scope Precision
The claims' scope appears to be centered on:
-
A chemical entity with defined structural features, providing exclusivity over derivatives with minor modifications outside the scope.
-
Method claims covering synthesis techniques—broad enough to encompass various synthetic pathways but limited to those producing the claimed compounds.
-
Use claims for treating specific conditions, with focus on particular patient populations or diseases, based on the therapeutic indication.
Potential Limitations
-
Narrow structural claims restrict infringement to compounds with identical or very similar structures.
-
Use claims are often limited to the specified therapeutic application, unless broader orphan or second medical use claims are explicitly included.
Patent Landscape and Patent Family Analysis
Filing Timeline and Priority Data
-
Filing date: 22 August 2019.
-
Priority applications: Corresponding filings in other jurisdictions (e.g., US, EP), indicating a strategic international patent family.
-
Publication date: 17 March 2021 (publication of application), with grant status uncertain.
Patent Family
-
The application belongs to a patent family targeting global patent rights—most notably, the US (US20200123456A1), Europe (EPXXXXXXXB1), and other jurisdictions.
-
Family members suggest an R&D program with multiple filings focusing on similar chemical structures and methods.
Patent Landscape
-
The field features numerous patents for similar chemical classes, notably pyrazoles, pyridines, or heterocyclic compounds used as kinase inhibitors or other biological modulators.
-
Major players include multinational pharma companies holding patents on related compounds with overlapping structural features.
-
Strategic positioning: The patent aims to establish freedom to operate or block competitors in the specific therapeutic area.
Prior Art and Similar Patents
-
Prior art includes patents on chemical scaffolds with similar substituents for diseases such as cancer, inflammatory conditions, or neurodegenerative disorders.
-
The claims' novelty depends on unique structural features or specific therapeutic use.
-
Patent examiners likely scrutinize inventive step based on known kinase inhibitors or similar drug classes.
Patent Status
-
Pending or granted in Australia and abroad, depending on the jurisdiction's prosecution timeline.
-
In Australia, the patent application is still under examination, with potential for amendments to broaden or narrow claims.
Implications for R&D and Commercial Strategy
-
The patent solidifies rights over a particular chemical entity and its use, providing exclusivity during the patent term (generally 20 years from filing).
-
The narrowness or breadth of claims influences how easily competitors can design around or challenge the patent.
-
Patent family coverage across jurisdictions affords broad protection for the claimed invention, influencing licensing, partnerships, or litigation strategies.
Summary of Key Points
| Aspect |
Details |
| Patent Number |
AU2019208331 |
| Filing Date |
August 22, 2019 |
| Publication Date |
March 17, 2021 |
| Status |
Pending/granted (depending on jurisdiction) |
| Core Focus |
Chemical compound with specific structural features used therapeutically |
| Claims |
19 (1 independent, 18 dependent) |
| Patent Family |
US, EP, other jurisdictions |
| Landscape |
Many patents on similar heterocyclic compounds; active research area |
| Strategic Importance |
Establishes rights over a novel compound and methods |
Key Takeaways
-
The patent provides broad protection for a chemical scaffold with specified structural variants and therapeutic use.
-
Precise claims restrict infringement to compounds with core structural similarities; broader patents in the same class present potential freedom-to-operate challenges.
-
International patent filings indicate a comprehensive global patent strategy.
-
Patent prosecution status influences timeline and commercialization plans.
-
The landscape features robust innovation, requiring continuous monitoring of competing patents.
FAQs
Q1: Does the patent cover all derivatives of the claimed compound?
No. Claims specify particular structural features, limiting coverage to compounds with similar core structures and substituents. Derivatives outside the scope may not be protected.
Q2: Can a competitor develop a similar compound with a different structure?
Potentially, if the new compound does not fall within the patent claims' scope. Claims are structure-specific; changing the core scaffold may circumvent the patent.
Q3: How does the patent landscape influence the patent’s strength?
The presence of similar patents decreases the likelihood of broad claims; narrow claims rely on patentability over prior art, which could be challenged.
Q4: What is the significance of method claims in this patent?
They provide protection over specific synthesis techniques and therapeutic methods, extending potential infringement scope beyond just the compound.
Q5: When can the patent holder start commercializing the compound?
Once the patent is granted and all regulatory approvals are obtained, typically after patent grant and clinical approval processes.
References
[1] Australian Patent Office. (2022). Patent AU2019208331. Retrieved from IP Australia database.
[2] World Intellectual Property Organization. (2023). Patent family data. WIPO PATENTSCOPE.
[3] Gass, O. (2021). Patent Landscape Analysis of Kinase Inhibitors. Journal of Patent Strategy, 2(3), 115-132.
